Ovid Therapeutics, a clinical-stage biotech developing treatments for rare neurological disorders, filed on Tuesday with the SEC to raise up to $86 million in an initial public offering.
The New York, NY-based company was founded in 2014 and it plans to list on the Nasdaq under the symbol OVID. Ovid Therapeutics filed confidentially on February 3, 2017. Citi and Cowen & Company are the joint bookrunners on the deal. No pricing terms were disclosed.
